Fanconi-Bickel syndrome is a rare autosomal recessive disorder due to mutations in the facilitative glucose transporter 2 (GLUT2 or SLC2A2) gene resulting in excessive glycogen storage predominantly in the liver and kidney. Previous case reports of this condition have described liver biopsies with glycogen storage and variable steatosis and/or fibrosis. Unlike in other types of glycogen storage disease, hepatocellular adenomas and carcinomas have not been described to date in this syndrome. A 6-year-old boy with consanguineous parents had short stature, poorly controlled rickets, hepatosplenomegaly, and renal tubular dysfunction clinically consistent with Fanconi-Bickel Syndrome. Sequencing of the SLC2A2 gene showed a homozygous variant of unknown significance [c.474A > C (p.Arg158Ser)] causing a missense mutation in an evolutionarily conserved residue. An incidental single hepatic lesion was discovered on imaging, and subsequent resection showed a 2.6 cm well-differentiated hepatocellular carcinoma with moderate atypia, diffuse immunoreactivity for glypican-3, and nuclear bcatenin, and with focal complete loss of the reticulin framework. The non-neoplastic liver showed marked glycogen accumulation with mild periportal fibrosis, rare bridging fibrosis, and no regenerative or adenomatous nodules. By electron microscopy, tumor cells had pleomorphic nuclei, prominent nucleoli, and scant cytoplasm with numerous mitochondria. Well-developed canaliculi were occasionally seen. The non-neoplastic liver showed glycogenosis with abundant cytoplasmic free (non-membrane bound) glycogen. Hepatocellular carcinoma should be considered as a possible complication of FanconiBickel syndrome. This well differentiated carcinoma did not appear to be associated with hepatic adenomatosis as has been described in some hepatocellular carcinomas associated with other hepatic glycogen storage disorders. The nuclear betacatenin immunoreactivity indicates a role for the Wnt signaling pathway in the pathogenesis of this tumor.
Introduction
Fanconi-Bickel syndrome (FBS) is an extremely rare autosomal recessive disorder due to mutations in the facilitative glucose transporter 2 (GLUT2 or SLC2A2), which results in excessive glycogen accumulation predominantly in the liver and kidneys. 1 The associated clinical phenotype includes impaired glucose and galactose tolerance with fasting hypoglycemia, hepatomegaly, and proximal renal tubular acidosis with associated hypophosphatemic rickets and failure to thrive. There is no specific therapy, but treatment includes compensation for renal losses of electrolytes, vitamin D and phosphorous supplementation and dietary modifications to stabilize glucose levels and restrict galactose. 2, 3 Although some patients die during childhood, there is an overall favorable prognosis, and survival into adulthood is possible. The range of phenotypes is variable, and even in patients with documented GLUT2 mutations, mild phenotypes may be observed. 4 The majority of patients with FBS have homozygous or compound heterozygous GLUT2 mutations, and most of these are unique mutations. 5 Although approximately 70% of FBS-associated mutations result in a truncated protein, missense mutations are also described. However, in some patients with classic phenotypic features, a GLUT2 mutation is not detected. In these patients, it has been hypothesized that either a mutation affecting gene expression or a mutation in a different gene in a similar or related biochemical pathway might explain the phenotype. 5 Unlike some forms of glycogen storage disease with a high risk of developing adenomas and hepatocellular carcinomas, no liver masses in FBS patients have been reported. Liver biopsies in cases of FBS have shown marked glycogen accumulation, steatosis, and variable fibrosis. 3, [6] [7] [8] [9] [10] [11] [12] Here, we report the first case of hepatocellular carcinoma arising in a child with FBS.
Case Report
The patient was a 6-year-old boy from Kuwait who was seen in consultation and found to have a clinical picture consistent with FBS. Features supporting this diagnosis included short stature (well under the third percentile), poorly controlled rickets, hepatosplenomegaly, enlarged kidneys, glucosuria, renal tubular dysfunction, and galactose intolerance. Findings unusual for FBS included a normal fasting tolerance and ultrasound findings suggestive of nephrocalcinosis. He was described as having mild craniofacial dysmorphism.
The patient's parents were first cousins with 2 other younger healthy children and no other family history of tubulopathy. Sequencing of the SLC2A2 gene showed a homozygous variant of unknown significance (c.474A > C (p.Arg158Ser). Although this variant has not previously been reported in FBS, it results in a missense mutation in a highly evolutionarily conserved residue located within an extracellular domain of the protein.
The patient's hepatosplenomegaly had first been noted at several months of age when he had a prolonged hospitalization for pneumonia. He was followed for his renal tubular dysfunction and growth failure with a presumptive diagnosis of FBS. A renal ultrasound, performed at 5 years of age to assess for nephrocalcinosis in the setting of renal tubular dysfunction, demonstrated a solid hypoechoic mass in the right lobe of the liver (Figure 1 ), possibly with an adjacent hyperechoic lesion, for which further characterization was recommended. MRI with the hepatobiliary contrast agent Eovist TM Figure 1 . Imaging findings. Ultrasound imaging (A) shows a well-circumscribed hypoechoic lesion in segment 6 of the liver, just adjacent to the lower pole of the right kidney. Subsequent MR imaging with the hepatobiliary contrast agent Eovist TM (Gd-EOB-DPTA; gadoxetate disodium) shows a solitary lesion characterized by increased signal intensity on T2-weighted imaging (B), early arterial phase enhancement following Eovist TM contrast administration (C), with washout of contrast on delayed hepatocellular phase imaging (D, E). These findings together with the restricted diffusion seen on DWI imaging (inset ADC map) (F) are consistent with a cellular neoplasm lacking any hepatocyte function and are characteristic of a neoplasm such as hepatocellular carcinoma.
(Gd-EOB-DPTA: gadoxetate disodium) was subsequently performed for further characterization of the lesion. Figure 1 (B) shows a solid heterogeneously hyperintense mass with restricted diffusion (Figure 1(F) ) that enhances with contrast during the arterial phase of imaging ( Figure 1(C) ), but which becomes hypointense on the delayed hepatobiliary phase images (Figure 1(D) and (E)), features that were concerning for neoplasm. Differential considerations included atypical adenoma and hepatocellular carcinoma, although adenoma was considered less likely based on opposed phase MR sequences that confirmed the absence of lipid in the lesion. His AFP prior to surgery was 22 (reference 0-15 ng/mL). Resection of the lesion was recommended.
Gross examination showed a 2.6 cm well demarcated, multinodular mass with a discontinuous pseudocapsule and prominent central nodule ( Figure 2 (A)). Microscopic examination confirmed that this was a well-differentiated hepatocellular carcinoma partially divided into nodules by fibrous bands (Figure 2(B) ). Consistent with the MRI showing restricted diffusion within the mass, the nodules were hypercellular and composed of tumor cells with high nuclear/cytoplasmic ratio, moderate nuclear pleomorphism with a prominent single nucleolus, and scant cytoplasm (Figure 2(C) and (D) ). Some of the nodules showed cholestasis and or marked steatosis, while the central nodule which had been identified grossly showed the highest nuclear/cytoplasmic ratio and had up to 4 mitotic figures per high-power field. There was patchy complete loss of the reticulin framework (Figure 3(A) ). Immunohistochemical stains showed diffuse, intense immunoreactivity for glypican-3 and for nuclear and cytoplasmic beta-catenin in tumor cells (Figure 3(B) and 3(C) ). Tumor cells were negative for AFP and CK19, and the Ki67 proliferative index was moderately high (Figure 3(D) ). By electron microscopy, in addition to the increased nuclear/cytoplasmic ratio, focally pleomorphic nuclei with prominent nucleolus and occasional canaliculi, the tumor cells also showed marked increased number of mitochondria and minimal microvesicular fat (Figure 4(A) ).
The non-neoplastic liver showed obvious hepatocellular cytoplasmic distention with free glycogen accumulation and no significant steatosis (in agreement with the MR findings) imparting a plant cell-like appearance to the hepatocytes (Figure 4(B) ). There was no ballooning, acidophil bodies, or inflammation. Occasional bridging fibrosis was present, but most of liver showed only mild fibrosis. Ultrastructurally, the non-neoplastic liver showed markedly increased non-membrane bound cytoplasmic glycogen with displacement of cytoplasmic organelles to perinuclear and subplasmalemmal locations, consistent with glycogen storage disease (Figure 4(C) ). Oncologically, a decision was made to observe the patient post-resection with serial imaging studies and AFP levels. There is limited data regarding the appropriate approach to therapy following complete resection of a well-differentiated HCC arising in the context of a child with an abnormal liver. Two months postresection, an AFP was documented within normal range at 14 ng/mL.
Discussion
To our knowledge, this is the first case report of hepatocellular carcinoma arising in a patient with FBS. The non-neoplastic liver around the tumor had typical findings of glycogen storage disease with little fibrosis, as expected based on previous biopsy descriptions of FBS patients and the underlying metabolic defect. GLUT2 is normally expressed in enterocytes, proximal tubular epithelial cells, pancreatic beta cells, and hepatocytes. 13 Animal studies have shown that in addition to its requirement for glucose reabsorption in the kidney, GLUT2 is the main glucose transporter in the liver and pancreatic beta cells. Hepatocellular GLUT2 is normally expected to take up glucose during feeding and to release glucose during fasting phases. Accumulation of hepatocellular glycogen in FBS is speculated to be due to decreased transport of glucose out of hepatocytes. The increased intracellular glucose would then inhibit glycogen degradation. 3 The mechanisms of tumorigenesis in FBS and in other glycogen storage diseases (GSDs) are unknown. Hepatocellular adenomas and carcinomas arise with variable frequency in other types of GSD affecting the liver. These neoplasms are particularly common in GSD type Ia, the most common type of GSD affecting the liver. These patients may develop multiple adenomas which are at risk for malignant transformation. In contrast, mass lesions are more rarely reported in other glycogen storage diseases including types III, IV, and VI. [14] [15] [16] It has been speculated that, as in other chronic liver diseases, cirrhosis may be a contributing factor to tumorigenesis in some types of GSD. 15 However, GSD type I patients have a relatively high rate of tumor formation despite limited fibrosis. Thus, it seems that another mechanism may be at work. GSD type Ia is the best characterized model of neoplasia arising in livers with glycogenosis. In GSD type Ia, patients have elevated levels of markers for oxidative stress, and mouse models of this disease show altered levels of glycolytic enzymes, increased hepatocellular apoptosis, and ongoing liver damage and inflammation. 17, 18 Some or all of these factors, therefore, even in the absence of cirrhosis, may contribute to the development of neoplasia in these patients. Based in part on these observations, the American College of Medical Genetics and Genomics 19 recommends that pediatric patients with GSD-1 be screened by abdominal US at diagnosis, and then every 1-2 years, with CT or MRI recommended every 6-12 months for older patients and for pediatric patients in whom lesions are identified by screening US, although there is no evidence that routine surveillance is effective in identifying transformation of adenomatous lesions into hepatocellular carcinoma 19, 20 A recent classification of hepatocellular adenomas based on pathological and molecular abnormalities has described 4 main types of adenomas. These are (1) those with HNF-1a inactivating mutations which are characterized by marked steatosis, (2) those with b-catenin mutations, (3) those with inflammatory features which are associated with several different oncogene mutations, and (4) all others. 21 Among patients with GSD type I adenomas, divergent results have been reported in small case series, with 1 report showing that all hepatocellular adenomas had steatotic foci, and 28% were b-catenin activated (a higher proportion than reported in sporadic adenomas), while another report demonstrated no b-catenin mutations and instead found that all GSD type I nodules had features of inflammatory hepatocellular adenoma. 22, 23 Although the discrepancy in these reports may reflect the small sample sizes, a high rate of b-catenin mutation would be more consistent with the known risk of malignant transformation in these patients, since adenomas with b-catenin mutations are associated with an increased risk of malignant transformation. In fact, it has been argued that b-catenin positive atypical adenomas may be well differentiated carcinomas based on the fact that and in cases with areas of carcinoma adjacent to apparent adenoma, both types of tumor foci show similar cytogenetic and immunohistochemical features. 24 Our patient's carcinoma was incompletely divided into nodules by fibrous bands. And, while the degree of atypia and mitotic activity were present throughout the entire lesion and classifiable as moderate to severe dysplasia of the small cell type, there were no discrete areas that could be clearly deemed to be a pre-existing adenoma. Moreover, the entire lesion was positive for glypican 3, which is negative in normal liver and in hepatocellular adenomas, but positive in hepatocellular carcinomas and occasional dysplastic nodules. 25 There was therefore no convincing evidence that the HCC arose from a direct malignant transformation of an adenoma.
The patient's homozygous missense mutation results in the conversion of an evolutionarily conserved arginine to serine at codon 158. While this mutation has not been reported previously, other missense mutations have been identified in patients with FBS. In this case, the presence Figure 4 . Electron microscopy and histopathology of the nonneoplastic liver. Ultrastructurally, tumor cells (arrows) have a high nuclear/cytoplasmic ratio, pleomorphic nuclei with prominent single nucleolus, and a relatively small cytoplasm filled with mitochondria (A). The non-neoplastic liver by light microscopy reveals clear distended hepatocytes with the characteristic features of glycogenosis (B). Excessive cytoplasmic free glycogen was demonstrated ultrastructurally (C). Note displacement of organelles to the cytoplasmic periphery and around the nuclear envelope. A few microvesicular fat droplets are also seen.
of a mutation within a highly conserved residue of GLUT2 in a patient with major clinical features of FBS strongly suggests a causal relationship. Further research is required to functionally characterize this and other GLUT2 mutations, particularly since the spectrum of phenotypes associated with germline mutations in GLUT2 is broad. Indeed, GLUT2 mutations have also been reported in patients with autosomal recessive proximal tubulopathy with hypercalciuria who do not have abnormal glycogen storage, and genome wide association studies have shown allelic variants of GLUT2 to be associated with type 2 diabetes and cardiovascular disease. [26] [27] [28] Such characterization, however, is likely to be difficult since most mutations found in FBS are unique to each family. Their role in HCC development will be particularly difficult to elucidate since hepatocellular neoplasms have not been previously reported in patients with this syndrome. The role for surveillance imaging or serial serum AFP levels to screen for HCCs in patients with FBS, as is pursued for patients diagnosed with other glycogen storage diseases therefore remains unclear.
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